| Sign In | Join Free | My benadorassociates.com |
|
| Categories | Vacuum Blood Test Tube |
|---|---|
| Brand Name: | Orsin |
| Model Number: | Gel Clot ActivatoR |
| Certification: | ISO 13485 |
| Place of Origin: | China |
| MOQ: | 100/pcs |
| Price: | Negotiation |
| Payment Terms: | L/C, D/A, D/P, T/T, Western Union |
| Supply Ability: | 20million/pcs/moth |
| Delivery Time: | 1-4 weeks |
| Capacity: | 5ml |
| Logo Printing: | Available for big orders (>30000 PCS) |
| Sterile: | Non-Sterile |
| Moq Limit: | 30000 PCS |
| Shipping Options: | Sea, air, or train |
| Anticoagulant Properties: | Efficient and stable |
| Application Scenarios: | Liquid Biopsy |
| Tube Size: | 13*75mm、13*100mm、16*100mm |
| Clolor: | purple |
| Characteristic: | Excellent stability |
| Material: | Glass/PET |
| Cloro: | Can be customized |
| Coagulant: | Orsin-specific coagulant |
| Company Info. |
| Shanghai Orsin Medical Technology Co., Ltd. |
| Verified Supplier |
| View Contact Details |
| Product List |
Practical Uses & Functions:
Stabilization: Specifically designed for the long-term, room temperature stabilization of cell-free DNA (cfDNA) in blood, plasma, serum, and other liquid samples, preventing degradation.
Facilitated Transport: Enables safe sample shipping without freezing, significantly reducing cold chain logistics costs and complexity.
Streamlined Workflow: Samples can be drawn directly into the tube, eliminating the need for immediate centrifugation or freezing, simplifying pre-analytical processing.
Release of cfDNA: Stabilizing agents promote cell lysis to release cell-free nucleic acids into circulation and stabilize them immediately.
Nuclease Inhibition: Contains potent inhibitors that effectively inactivate nucleases (e.g., DNase) in the sample, preventing cfDNA degradation during storage and transport.
Minimize gDNA Contamination: Optimized formulation minimizes white blood cell lysis, thereby reducing background genomic DNA (gDNA) contamination and improving cfDNA purity.
Key Packaging Advantages:
Room Temperature Stability: Revolutionizes sample storage by allowing long-term stabilization at ambient temperature (often days to weeks or even months), eliminating reliance on dry ice or ultra-low freezers.
Draw-and-Stabilize Simplicity: Extremely easy to use - mix blood immediately after draw, bypassing the need for prompt centrifugation.
High Fidelity Preservation: Superior protection ensures cfDNA integrity, fragment profile, and concentration, providing high-quality template for downstream high-sensitivity assays (e.g., NGS, qPCR, ddPCR).
Global Compatibility: Cold-chain independence facilitates remote sample collection, centralized shipping, and international transport, enabling multi-center studies and global projects.
Safety & Reliability: Leak-proof design ensures biosafety; high batch-to-batch consistency guarantees reliable and reproducible results.
Broad Compatibility: Compatible with various automated liquid handling systems and downstream DNA extraction kits.
Application Scenarios:
Liquid Biopsy: Cancer early detection, diagnosis, companion diagnostics, treatment response monitoring, recurrence surveillance, and resistance assessment (especially for ctDNA analysis).
Non-Invasive Prenatal Testing (NIPT): Screening for fetal chromosomal aneuploidies (e.g., Down Syndrome) by analyzing cell-free fetal DNA (cffDNA) from maternal peripheral blood.
Transplant Rejection Monitoring: Detecting donor-derived cell-free DNA (dd-cfDNA) to assess organ transplant rejection.
Infectious Disease Detection: Detecting cell-free DNA from pathogens (e.g., viruses, bacteria).
Genetic Disease Research: Studying circulating fetal or disease-associated DNA.
Biobanking: Long-term, room-temperature archiving of precious liquid biopsy samples for future research.
Multi-Center Clinical Trials: Simplifies sample collection, stabilization, and transport across geographically diverse sites, ensuring sample quality consistency.
Remote Area Sampling: Enables blood sample collection and stabilization in areas lacking cold chain infrastructure.
|